Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

China takes lead in CRISPR/Cas9 with start of first-ever clinical trial

Published 11/15/2016, 03:54 PM
China takes lead in CRISPR/Cas9 with start of first-ever clinical trial
  • The race to prove the efficacy of the CRISPR/Cas9 gene editing technology in humans is poised to move into high gear. A group led by oncologist Lu You at Sichuan University in Chengdu became the first to inject a person with cells edited with the technique when they dosed a patient with metastatic non-small cell lung cancer on October 28. The edited cells were disabled from coding for the protein PD-1, an immune response dampener called an immune checkpoint.
  • Lu received ethical approval from the hospital review board in July but the injections, originally pegged for August, were delayed because culturing and amplifying the cells took longer than expected. The procedure apparently went well and the patient is due for a second injection.
  • The trial will enroll only 10 subjects, each of whom will receive two - four injections.
  • A study in the U.S., led by the University of Pennsylvania's Carl June, is set to begin in Q1. It will assess three cancer-related genes edited by CRISPR/Cas9.
  • Related tickers: (CRSP +2.5%)(EDIT -3.4%)(NTLA +11.9%)

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.